1
|
Abdulaziz S, Almaqati AS, Komo K, Alahmadi A. Correlation of Disease Activity Scores and Routine Assessment of Patient Index Data (RAPID3) on a Multidimensional Health Assessment Questionnaire in Patients With Rheumatoid Arthritis: A Saudi Experience. Cureus 2023; 15:e44982. [PMID: 37822428 PMCID: PMC10564089 DOI: 10.7759/cureus.44982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/10/2023] [Indexed: 10/13/2023] Open
Abstract
Introduction This study aimed to analyze the correlation between Routine Assessment of Patient Index Data (RAPID3) and disease activity scores using the Disease Activity Score 28 (DAS28 erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP)), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI) in patients with rheumatoid arthritis (RA) attending a single rheumatology center in Jeddah. Methods A cross-sectional study of patients with RA who fulfilled the 2010 American College of Rheumatology criteria for the diagnosis of RA between June 2018 and November 2019 was conducted. The validated Arabic version of the multidimensional health assessment questionnaire (MDHAQ) was used. The data collected included demographic information, comorbid illnesses, concomitant medications, laboratory results, and disease activity measured using the DAS 28 ESR/CRP, CDAI, SDAI, and RAPID3. Results A total of 137 patients with RA were included in the analysis; the mean age was 53.1 (± 12) years, there were 122 (89%) females, and the mean disease duration was 8 (± 4) years. Forty-nine (44.5%) patients were treated with anti-tumor necrosis factor (anti-TNF), 53 (48.2%) with non-anti-TNF, 8 (7.3%) with Janus kinase (JAK) inhibitors, and 27 (20%) with synthetic disease-modifying drugs (sDMARD). The mean RAPID3 (0-10) score was 3.6 (± 2) for low disease activity. The mean DAS28 ESR was 4.16 (± 4) for moderate disease activity. The mean DAS CRP was 3.39 (± 1.2) for moderate disease activity. The mean CDAI was 13.4 (± 10.7) for moderate disease activity. The mean SDAI was 15.34 (± 11.8) for moderate disease activity. Pearson's correlations showed a strong correlation with DAS28 CRP (r=0.773, p < 0.001), SDAI (r=0.764,p < 0.001), CDAI (r=0.710, p < 0.001), and DAS28 ESR (r=0.283, p < 0.002). Conclusion RAPID3 significantly correlated with DAS28-CRP, SDAI, and CDAI scores in our patients. It is a simple, inexpensive, and patient-centered practical tool for assessing disease activity that can reflect the health-related quality of life and be easily implemented in clinical practice.
Collapse
Affiliation(s)
- Sultana Abdulaziz
- Department of Medicine/Rheumatology, King Fahad General Hospital, Jeddah, SAU
| | - Ahmed S Almaqati
- Department of Internal Medicine/Rheumatology, King Abdulaziz Medical City - Jeddah, Jeddah, SAU
- Department of Internal Medicine/Rheumatology, King Abdullah International Medical Research Center, Jeddah, SAU
| | - Kalthom Komo
- Department of Medicine/Rheumatology, King Fahad General Hospital, Jeddah, SAU
| | - Abdullah Alahmadi
- Department of Medicine/Rheumatology, King Fahad General Hospital, Jeddah, SAU
| |
Collapse
|
2
|
Omair MA, Al Rayes H, Khabsa J, Yaacoub S, Abdulaziz S, Al Janobi GA, Al Khalaf A, Al Mehmadi B, Al Nassar M, AlBalawi F, AlFurayj AS, Al-Jedai AH, Almalag HM, Almudaiheem HY, AlRehaily A, Attar MA, El Kibbi L, Halabi H, Hasan M, Singh JA, Fraenkel L, Akl EA. Recommendations for the treatment of rheumatoid arthritis in Saudi Arabia: adolopment of the 2021 American College of Rheumatology guidelines. BMC Rheumatol 2022; 6:70. [PMID: 36414983 PMCID: PMC9682746 DOI: 10.1186/s41927-022-00301-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 08/08/2022] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND The 2021 American College of Rheumatology (ACR) rheumatoid arthritis (RA) guideline considers the specific context of the United States which differs from that of Saudi Arabia in many aspects that may impact recommendations. The objective of this project was to adapt a set of prioritized recommendations from the 2021 ACR guideline for the treatment of rheumatoid arthritis RA for the context of Saudi Arabia, by the Saudi Society for Rheumatology (SSR). METHODS The process followed the GRADE-ADOLOPMENT methodology, and the reporting adhered to the RIGHT-Ad@pt checklist. Working groups included a coordination group and a 19-member panel representing different stakeholder groups. The Evidence to Decision (EtD) tables included evidence on health effects from the source guideline and contextual information from the Saudi setting. RESULTS The panel prioritized and adapted five recommendations from the source guideline. The process led to modifying two out of the five prioritized recommendations, all listed here. In naive patients with low disease activity, methotrexate (MTX) is conditionally recommended over sulfasalazine (SSZ) (modified direction); hydroxychloroquine (HCQ) is conditionally recommended over SSZ (unmodified). Initiation of csDMARDs with short-term glucocorticoids is conditionally recommended over csDMARDs alone in naive patients with moderate to high disease activity (modified direction). Switch to subcutaneous MTX is conditionally recommended over addition/switch to alternative DMARD(s) in patients taking oral MTX who are not at target (unmodified). Discontinuation of MTX is conditionally recommended over gradual discontinuation of the bDMARD or tsDMARD for patients taking MTX plus a bDMARD or tsDMARD who wish to discontinue a DMARD (unmodified). CONCLUSION Rheumatologists practicing in Saudi Arabia can use the adoloped recommendations generated by this project while adopting the rest of the recommendations from the 2021 ACR guidelines.
Collapse
Affiliation(s)
- Mohammed A. Omair
- grid.56302.320000 0004 1773 5396Rheumatology Unit, Department of Medicine, King Saud University, PO Box 2925, Riyadh, 11461 Saudi Arabia
| | - Hanan Al Rayes
- grid.415989.80000 0000 9759 8141Division of Rheumatology, Department of Internal Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Joanne Khabsa
- grid.411654.30000 0004 0581 3406AUB Grade Center, American University of Beirut Medical Center, Beirut, Lebanon
- grid.411654.30000 0004 0581 3406Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon
| | - Sally Yaacoub
- grid.411654.30000 0004 0581 3406AUB Grade Center, American University of Beirut Medical Center, Beirut, Lebanon
- grid.411654.30000 0004 0581 3406Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon
| | - Sultana Abdulaziz
- grid.415296.d0000 0004 0607 1539Division of Rheumatology, Department of Medicine, King Fahad Hospital, Jeddah, Saudi Arabia
| | - Ghada A. Al Janobi
- grid.415458.90000 0004 1790 6706Rheumatology Unit, Department of Medicine, Qatif Central Hospital, Qatif, Saudi Arabia
| | - Abdulaziz Al Khalaf
- grid.56302.320000 0004 1773 5396Rheumatology Unit, Department of Medicine, King Saud University, PO Box 2925, Riyadh, 11461 Saudi Arabia
| | - Bader Al Mehmadi
- grid.449051.d0000 0004 0441 5633Division of Rheumatology, Department of Medicine, College of Medicine, Majmaah University, Al-Majmaah, 11952 Saudi Arabia
| | - Mahasin Al Nassar
- grid.56302.320000 0004 1773 5396Department of Obstetrics and Gynecology, King Saud University, Riyadh, Saudi Arabia
| | - Faisal AlBalawi
- grid.415277.20000 0004 0593 1832Section of Rheumatology, Department of Internal Medicine, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Abdullah S. AlFurayj
- Rheumatology Unit, Department of Medicine, Buraidah Central Hospital, B.C.H, Buraidah, Qassim Saudi Arabia
| | - Ahmed Hamdan Al-Jedai
- grid.415696.90000 0004 0573 9824Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia
- grid.411335.10000 0004 1758 7207College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - Haya Mohammed Almalag
- grid.56302.320000 0004 1773 5396Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Hajer Yousef Almudaiheem
- grid.415696.90000 0004 0573 9824Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia
| | - Ali AlRehaily
- grid.415462.00000 0004 0607 3614Department of Medicine, Section of Rheumatology, Security Forces Hospital Program, Riyadh, Saudi Arabia
| | - Mohammed A. Attar
- grid.413494.f0000 0004 0490 2749Division of Rheumatology, Department of Medicine, Al Hada Armed Forces Hospital, Taif, Saudi Arabia
| | - Lina El Kibbi
- Division of Rheumatology, Department of Internal Medicine, Specialized Medical Center, Riyadh, Saudi Arabia
| | - Hussein Halabi
- grid.415310.20000 0001 2191 4301Section of Rheumatology, Department of Internal Medicine, King Faisal Specialist Hospital and Research Center-Jeddah, Jeddah, Saudi Arabia
| | - Manal Hasan
- grid.411975.f0000 0004 0607 035XDivision of Rheumatology, Department of Internal Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
| | - Jasvinder A. Singh
- grid.280808.a0000 0004 0419 1326Medicine Service, VA Medical Center, 700 19th St S, Birmingham, AL 35233 USA
- grid.265892.20000000106344187Department of Medicine at the School of Medicine, University of Alabama at Birmingham (UAB), 510 20th Street S, Birmingham, AL 35294-0022 USA
- grid.265892.20000000106344187Department of Epidemiology at the UAB School of Public Health, Ryals Public Health Building, 1665 University Blvd, Birmingham, AL 35294-0022 USA
| | - Liana Fraenkel
- grid.414445.4Berkshire Medical Center, Pittsfield, MA USA
- grid.47100.320000000419368710Yale University School of Medicine, New Haven, CT USA
| | - Elie A. Akl
- grid.22903.3a0000 0004 1936 9801Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
- grid.25073.330000 0004 1936 8227Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON Canada
| |
Collapse
|
3
|
Karremah MF, Hassan RY, Faloudah AZ, Alharbi LK, Shodari AF, Rahbeeni AA, Alharazi NK, Binjabi AZ, Cheikh MM, Manasfi H, Abdulaziz S, Hussein AH, Alhazmi A, Almoallim H. From Symptoms to Diagnosis: An Observational Study of the Journey of SLE Patients in Saudi Arabia. Open Access Rheumatol 2022; 14:103-111. [PMID: 35791408 PMCID: PMC9250784 DOI: 10.2147/oarrr.s362833] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 05/26/2022] [Indexed: 11/23/2022] Open
Abstract
Background and Objectives Early diagnosis and treatment is associated with improved outcomes in patients with systemic lupus erythematosus (SLE). Studying the journey of SLE patients in Saudi Arabia is essential to direct future health-care plans. Patients and Methods This is a cross-sectional, multicenter study. Eligibility criteria included a diagnosis of SLE that was confirmed by a rheumatologist. Patients younger than 18 at the time of interview were excluded. Primary objectives were to determine time from first symptoms to initial physician visit (Lag 1), time from initial physician visit to encounter with rheumatologist (Lag 2), time from first visit to a rheumatologist to diagnosis of SLE (Lag 3), and time from diagnosis to start of treatment (Lag 4). Secondary objectives were to determine the number and specialty of physicians seen by patients, the speciality type that confirmed the diagnosis, first symptoms experienced, and age at first diagnosis of SLE. Results Three hundred patients (92.3% women) with SLE were evaluated. Mean age at diagnosis was 29.92 years. Mean disease duration was 8.1 years. The majority were college educated (43.0%). The most common initial symptom was joint pain (68%), followed by skin rash (23%), and fever (3.7%). Lag 1 was less than one month in 68.2% of patients. Lag 2 was less than one month in 33.4% of patients and exceeded one year in 25.8%. Lag 3 was less than 1 month in 68.7% of patients. Lag 4 was less than one month in 94.4% of patients. The diagnosis of SLE was made most frequently by rheumatologists (80%). Evaluation by primary care, orthopedic and dermatology physicians were associated with delays in diagnosis. Conclusion Delay was marked in Lag 2. Causes of delay included evaluation by non-specialists and visiting higher numbers of physicians before diagnosis confirmation.
Collapse
Affiliation(s)
- Mishal F Karremah
- Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia
| | - Rola Y Hassan
- Department of Medicine, Division of Rheumatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.,Alzaidi Chair of Research in Rheumatic Diseases, Umm Alqura University, Makkah, Saudi Arabia
| | - Ammar Z Faloudah
- Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia
| | - Lujain K Alharbi
- Department of Medicine, Division of Rheumatology, King Fahad Hospital, Madinah, Saudi Arabia
| | - Albraa F Shodari
- Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia
| | - Ahmad A Rahbeeni
- Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia
| | - Nouf K Alharazi
- Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia
| | - Ahmad Z Binjabi
- Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia
| | - Mohamed M Cheikh
- Alzaidi Chair of Research in Rheumatic Diseases, Umm Alqura University, Makkah, Saudi Arabia.,Department of Medicine, College of Medicine, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia
| | - Hanadi Manasfi
- Department of Medicine, Specialized Medical Center, Riyadh, Saudi Arabia
| | - Sultana Abdulaziz
- Department of Medicine, King Fahad General Hospital, Jeddah, Saudi Arabia
| | - Albadr Hamza Hussein
- Department of Medicine, Division of Rheumatology, King Fahad Hospital, Madinah, Saudi Arabia
| | - Ahmed Alhazmi
- Department of Medicine, Division of Rheumatology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
| | - Hani Almoallim
- Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia.,Alzaidi Chair of Research in Rheumatic Diseases, Umm Alqura University, Makkah, Saudi Arabia.,Department of Medicine, Dr. Sameer Abbas Hospital, Jeddah, Saudi Arabia
| |
Collapse
|
4
|
Al Rayes H, Abdulaziz S, Alotaibi AM, Alaithan MA, Attar M, Daghasi H, Melibari R, Althagafi AH, Elnady B. Adverse Impact of Rheumatoid Arthritis on Pregnancy Outcomes: A Saudi Arabia Prospective Multicenter Study. Open Access Rheumatol 2021; 13:167-175. [PMID: 34163264 PMCID: PMC8214560 DOI: 10.2147/oarrr.s315867] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 05/14/2021] [Indexed: 12/19/2022] Open
Abstract
Background Rheumatoid arthritis (RA) is associated with adverse pregnancy outcomes and postpartum complications, especially with severe disease activity. Objective The current study aimed to compare the pregnancy outcomes in patients with RA and healthy controls as well as to assess the impact of disease-related variables, medications and disease activity on pregnancy and neonatal-related outcomes in the Saudi population. Methods This prospective multicenter study included pregnant female patients with RA from three tertiary centers in Saudi Arabia. The demographics, disease activity scoring (DAS28-CRP), medication before and during pregnancy, pregnancy-related outcomes, and complications in comparison to age-matched healthy female controls were noted. Results A total of 77 pregnant patients with RA and 250 healthy age-matched pregnant controls were included in the study. A total of 67.53% were in remission before conception (DAS28CRP ≤2.6), and 81.8% of pregnancies were planned. Age of conception, preterm labor, neonatal intensive care unit (NICU) admission and low birth weight were statistically significant (p <0.05) and higher in RA patients than in healthy controls. Longer disease duration (p <0.001), and high C-reactive protein and erythrocyte sedimentation rate levels before conception (p ≤0.001) were statistically associated with preterm NICU admission. There was statistically significant association between mild (p = 0.015) or moderate to severe DAS28-CRP (p = 0.001) and RA patients regarding pregnancy outcomes. The classification table obtained from the logistic model showed patients with mild and moderate-severe DAS28-CRP have significantly high chances of having an adverse pregnancy outcome. Conclusion RA has a negative impact on pregnancy-related outcomes. Higher disease activity is considered a major risk; thus, tight disease control should be aimed. Planned pregnancy follow-up is associated with better pregnancy outcomes.
Collapse
Affiliation(s)
- Hanan Al Rayes
- Rheumatology Division, Department of Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Sultana Abdulaziz
- Division of Rheumatology, Department of Medicine, King Fahad Hospital, Jeddah, Saudi Arabia
| | | | - Mufaddal Adil Alaithan
- Rheumatology Division, Department of Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Mohammed Attar
- Division of Rheumatology, Department of Medicine, Al Hada Armed Forces Hospital, Taif, Saudi Arabia
| | - Hassan Daghasi
- Division of Rheumatology, Department of Medicine, Al Hada Armed Forces Hospital, Taif, Saudi Arabia
| | - Rand Melibari
- Division of Rheumatology, Department of Medicine, King Fahad Hospital, Jeddah, Saudi Arabia
| | - Ali H Althagafi
- Division of Rheumatology, Department of Medicine, Al Hada Armed Forces Hospital, Taif, Saudi Arabia
| | - Basant Elnady
- Division of Rheumatology, Department of Medicine, Al Hada Armed Forces Hospital, Taif, Saudi Arabia.,Rheumatology, Rehabilitation and Physical Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt
| |
Collapse
|
5
|
Abdulaziz S, Halabi H, Bahlas S, Attar S, Dessougi M, Alhouri A, Taruti A, Alrayes H, Albeity AHA. AB0366 DIFFUSE ALVEOLAR HEMORRHAGE IN LUPUS NEPHRITIS PATIENTS: MULTICENTER RECTROSPECTIVE STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Diffuse alveolar hemorrhage (DAH) is a rare and potentially lethal complication of systemic lupus erythematosus (SLE) with a high mortality rate. It occurs more frequently in patients with lupus nephritis (LN).Objectives:The aim of our study is to explore the characteristics of patients that develop DAH with lupus nephritis, risk factors that predispose DAH, treatment response and outcomes.Methods:Multicenter retrospective cohort study was undertaken including 6 centers in Saudi Arabia from 2002 to 2018. Systemic lupus erythematosus patients meeting the SLICC criteria with lupus nephritis (biopsy proven or proteinuria or renal impairment due to lupus) presenting with diffuse alveolar hemorrhage (fulfilling a predefined criteria) were included in the study. An identical number of control group with lupus nephritis was also studied. Data was obtained from medical records by using a data sheet: demographics including age, gender, diagnosis, date of diagnosis of lupus, date of presentation of alveolar hemorrhage, clinical presentation, detection of alveolar hemorrhage proved by radiology, lavage or biopsy and laboratory parameters: including level of hemoglobin before and during DAH, sign of activity, treatment and outcome of DAH. Identification of risk factors predisposing to DAH in lupus nephritis patients was analyzed.Results:We identified 23 cases of DAH with lupus nephritis, all fulfilling the criteria. Mean age at presentation of DAH was 31.09 ± 12.6 years ranging from 14-57 years, of which 87 % were females. 13 patients 56.5% had Class 4 LN and 21.7% had Class 4 and 5 LN on renal pathology. DAH occurred at a mean of 6.5 years ±3.8 in 13/23 patients with LN. Shortness of breath 95%, new chest x ray finding 95.7% and mean drop of haemoglobin of 2.72 gm/dl ±0.97 were more frequent at presentation of DAH with LN patients. High SLE disease activity - SELENA SLEDAI 2K was 38.56 ±19.3 was present at the onset of DAH. All were treated with methyprednisone,15/23 (65.2%) underwent mechanical ventilation and plasmapheresis was done in 21/23 patients (91.3%). Cyclophosphamide was given in 14/21 patients (60.9%), Intravenous immunoglobulins were given in 14/23 patients (65.2%) and dialysis was done in 12/23 patients (52.2%). Mortality occurred 8 patients 34.8 %. In comparison with the LN group, a mean haemoglobin of 7.56 ± 1.3, CNS involvement, vasculitis and fever>38% were of statistically significance P value: <0.001,0.02,0.03 and 0.03 respectively.Conclusion:In this multicenter cohort series with DAH in LN patients CNS involvement, vasculitis and fever>38 were associated in the occurrence of DAH. Mortality was low in our cohort in comparison to previous series which may be explained by early diagnosis and use of aggressive management.Well designed prospective studies are required to identify high risk patients for preventing this serious complication.References:[1]Eagen JW, Memoli VA, Roberts JL, et al. Pulmonary hemorrhage in systemic lupus erythematosus. Medicine (Baltimore) 1978; 57:545.[2]Badsha H, Teh CL, Kong KO, et al. Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 2004; 33:414.[3]Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76:192.[4]Hsu BY, Edwards DK 3rd, Trambert MA. Pulmonary hemorrhage complicating systemic lupus erythematosus: role of MR imaging in diagnosis. AJR Am J Roentgenol 1992; 158:519.Disclosure of Interests:None declared
Collapse
|
6
|
Abdulaziz S. Chemotherapy versus combined chemoradiotherapy: Survival patterns among elderly patients with limited stage small cell lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy445.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Abdulaziz S, Halabi H, Omair MA, Attar S, Alghamdi A, Shabrawishi M, Neyazi A, Alnazzawi H, Meraiani N, Almoallim H. Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series. Eur J Rheumatol 2017; 4:194-199. [PMID: 29164002 DOI: 10.5152/eurjrheum.2017.17003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2017] [Accepted: 04/10/2017] [Indexed: 12/27/2022] Open
Abstract
Objective Reactivation of viral hepatitis B (HBV) and C (HCV) has been reported in various case reports of patients with arthritis on biological therapy. The objective of this study was to describe the clinical characteristics and outcomes of arthritis patients with HBV or HCV treated with biological therapy. Material and Methods This is a retrospective case series including all patients above 13 years of age with arthritis patients from four centers in Saudi Arabia with concurrent chronic viral hepatitis infection (HBV or HCV) who received biological agents in the rheumatology clinics during their course of their disease from duration of the disease onset until last outpatient visit up to November 2015. Demographic information, full details about the hepatitis status of each patient, rheumatic disease diagnosis and different therapies used were reviewed. Results We identified 10 cases each with HBV and HCV on biological therapy. The mean age in the HBV group was 51 (34-85) years and 80% were females. Eight patients had rheumatoid arthritis (RA), one patient had RA/systemic lupus erythematosus, and one had human immunodeficiency virus related-arthritis. Seven were chronic inactive HBsAg carriers and three had chronic active HBV. Nine HBV patients received prophylactic antiviral therapy. Two cases with chronic HBV had reactivation with no elevation of the transaminases.The mean age in the HCV group was 54 (23-79) years and all were female RA patients. Three had detectable hepatitis C virus-ribonuecleic acid (HCV-RNA) before the start of biological therapy. Nine HCV patients received antiviral treatment and seven had a sustained virologic response (SVR) before start of biological treatment. Three patients had detectable HCV-RNA during the course of biological therapy. One of the three was a non-responder and two were relapsers. One of the patients with HCV relapse was started on sofosbuvir plus ribavirin and achieved SVR on follow-up. Conclusion We report the successful use of biological therapy in arthritis patients with hepatitis B infection with antiviral therapy with no detoriation of their viral status. Due to the lack of sufficient prospective studies demonstrating the rate of HCV flare on biological therapy, caution should be exercised and careful monitoring with liver enzymes and viral load is mandated in vulnerable HCV RNA patients. Treatment should be individualized by the rheumatologist in collaboration with the hepatologist to minimize complications.
Collapse
Affiliation(s)
- Sultana Abdulaziz
- Unit of Rheumatology, Department of Medicine, King Fahd Hospital, Jeddah, Saudi Arabia
| | - Hussein Halabi
- Department of Medicine, King Faisal Specialist Hospital, Jeddah, Saudi Arabia
| | - Mohammed A Omair
- Division of Rheumatology, Department of Medicine, King Saud University College of Medicine, Riyadh, Saudi Arabia
| | - Suzan Attar
- Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Abdullah Alghamdi
- Unit of Gastroenterology, Department of Medicine, King Fahd Hospital, Jeddah, Saudi Arabia
| | | | - Abdulwahab Neyazi
- Department of Medicine, Umm Alqura University School of Medicine, Makkah, Saudi Arabia
| | - Haneen Alnazzawi
- Department of Medicine, Umm Alqura University School of Medicine, Makkah, Saudi Arabia
| | - Nuha Meraiani
- Department of Medicine, King Faisal Specialist Hospital, Jeddah, Saudi Arabia
| | - Hani Almoallim
- Department of Medicine, Umm Alqura University School of Medicine, Makkah, Saudi Arabia.,Department of Medicine, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.,Alzaidi Chair of Research Diseases, Umm Alqura University School of Medicine, Makkah, Saudi Arabia
| |
Collapse
|
8
|
Almoallim H, Abdulaziz S, Fallatah E, Alhazmi H, Meraiani N, Bazuhair T, Mansour M, Tayeb A, Fathaldin O. Clinical characteristics and outcomes of cancer patients with post-chemotherapy arthritis: a retrospective case series report. Open Access Rheumatol 2017; 9:111-116. [PMID: 28615978 PMCID: PMC5460656 DOI: 10.2147/oarrr.s134816] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE The objective of this report was to describe the demographics, clinical characteristics and outcomes of patients with cancer presenting with arthritis following chemotherapy in Jeddah, Saudi Arabia. PATIENTS AND METHODS This is a retrospective case series report. We included any patient ≥18 years of age with an established diagnosis of cancer who had received standard therapeutic intervention and was subsequently diagnosed with arthritis after developing rheumatic symptoms either during or after treatment. Patients with clinical evidence of arthritis at the time of their cancer diagnosis were excluded. RESULTS Seven cases from different centers were identified. Breast cancer was the most common type of cancer reported. The diagnosis of arthritis was established by a rheumatologist. Bilateral involvement of the metacarpophalangeal and proximal interphalangeal joints was the most common presentation. The knee, back, shoulder and wrist joints were less affected. Following treatment, one patient experienced complete resolution of symptoms, four patients symptomatically improved and one patient had no improvement. CONCLUSION Arthritis can develop both during and after treatment of a malignancy. Solid tumors seem to be more commonly associated with this phenomenon. In this case series, the prognosis was poor as the majority of patients developed persistent arthritis.
Collapse
Affiliation(s)
- Hani Almoallim
- Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah.,Department of Medicine, King Faisal Specialist Hospital, Jeddah.,Alzaidi Chair of Research in Rheumatic Diseases, Umm Al-Qura University, Makkah
| | - Sultana Abdulaziz
- Rheumatology Unit, Department of Medicine, King Fahad Hospital, Jeddah
| | - Eilaf Fallatah
- Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah
| | - Haya Alhazmi
- Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah
| | - Nuha Meraiani
- Department of Medicine, King Faisal Specialist Hospital, Jeddah
| | - Tuqa Bazuhair
- Department of Medicine, King Abdullah Medical City, Makkah
| | - Mohammed Mansour
- Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah
| | - Anan Tayeb
- Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah
| | - Omar Fathaldin
- Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
9
|
Hammoudeh M, Abdulaziz S, Alosaimi H, Al-Rayes H, Aldeen Sarakbi H, Baamer M, Baraliakos X, Dahou Makhloufi C, Janoudi N, Shirazy K, Sieper J, Sukhbir U. Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus. J Int Med Res 2016; 44:216-30. [PMID: 26811411 PMCID: PMC5580068 DOI: 10.1177/0300060515611536] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 09/21/2015] [Indexed: 12/17/2022] Open
Abstract
Axial spondyloarthritis (SpA) is a spectrum of inflammatory disease with stages characterized by both nonradiographic and radiographic sacroiliitis. Nonradiographic axial SpA is associated with health-related quality-of-life impairment and may progress to ankylosing spondylitis. Axial SpA has a low prevalence in some countries in North Africa and the Middle East, and pooling of data and resources is needed to increase understanding of the regional picture. Early diagnosis and effective treatment are required to reduce disease burden and prevent progression. Anti-TNF therapy is recommended for patients with persistently high disease activity despite conventional treatment, and has been shown to be effective in patients without radiographic damage. Diagnostic delays can be an obstacle to early treatment and appropriate referral strategies are needed. In some countries, restricted access to magnetic resonance imaging and anti-TNF agents presents a challenge. In this article, a group of experts from North Africa and the Middle East evaluated the diagnosis and management of axial SpA with particular reference to this region.
Collapse
Affiliation(s)
- Mohammed Hammoudeh
- Department of Medicine, Weill Cornell Medical College Qatar, Hamad Medical Corporation, Doha, Qatar
| | | | - Hanan Alosaimi
- Rheumatology Section, Department of Internal Medicine/Rheumatology, Military Hospital, Jeddah, Saudi Arabia
| | - Hanan Al-Rayes
- Department of Medicine, Armed Force Hospital, Riyadh, Saudi Arabia
| | | | - Matouqa Baamer
- Department of Medicine, King Abdulaziz Hospital and Oncology Centre, Jeddah, Saudi Arabia
| | | | | | - Nahid Janoudi
- Department of Rheumatology, DSFH Hospital, Jeddah, Saudi Arabia
| | | | - Joachim Sieper
- Klinikum Benjamin Franklin, Freien Universität Berlin, Berlin, Germany
| | - Uppal Sukhbir
- Rheumatology Division, University Hospital, Sharjah, United Arab Emirates
| |
Collapse
|
10
|
Abdulaziz S. Rheumatoid arthritis-associated interstitial lung disease. Curr Pulmonol Rep 2015. [DOI: 10.1007/s13665-015-0121-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
11
|
Martin F, Manouvrier A, El Mechaal S, Chikouche R, Abdulaziz S, Grib M, Rény J, Daubin P, Coutelier M, Grange C. Intégration systématique des soins de support dans la prise en charge : proposition d’une modélisation après 2 années de mise en œuvre dans un service de pneumologie. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|